Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

On September 16, 2021

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Boeing, NASA Complete First Starliner Space Station Flight Test

Northrop Grumman Australia Announces Tech Showcase Winners

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022